- Home
- RMM vs PALI Comparison
RMM vs PALI Comparison
Compare RMM & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.92
Company Overview
Basic Information| Metric | RMM | PALI |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.6M | 240.2M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RMM | PALI |
|---|---|---|
| Price | $13.59 | $1.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 54.2K | ★ 3.9M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $12.55 | $0.55 |
| 52 Week High | $14.88 | $2.64 |
Technical Indicators
Market Signals| Indicator | RMM | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 40.76 | 52.78 |
| Support Level | $13.43 | $1.58 |
| Resistance Level | $13.99 | $2.05 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 26.32 | 65.44 |
Price Performance
Historical Comparison RMM
PALI
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.